Fibroblast growth factor binding protein (FGF‑BP), also known as HBp17, is a secreted glycoprotein that increases the bioavailability of FGFs (1). Mature FGF-BP is a 34 kDa, 211 amino acid (aa) O-glycosylated protein with five conserved intrachain disulfide bonds (2‑4). FGF-BP contains a heparin-binding domain (aa 110‑143) and a distinct FGF-binding region (aa 193‑243) (5). Mature human FGF‑BP shares 59% and 54% aa sequence identity with mouse and rat FGF-BP, respectively. FGF-BP is expressed throughout development and in adult squamous epithelium (2, 6). It is upregulated in injured skin, renal tubular epithelium, and spinal nerves as well as in carcinomas of the skin, colon, and pancreas (3, 7‑10). FGF-BP binds FGF-1, -2, -7, -10, and -22 which are secreted and sequestered in the extracellular matrix (ECM) (7, 11). The association of FGF-BP with heparan sulfate proteoglycans (HSPG) weakens HSPG attachment of FGFs and promotes their release (2, 8, 12, 13). FGF‑BP enhances the mitogenic effects of FGFs, thereby contributing to epithelial, endothelial, and neuronal tissue repair, angiogenesis, and tumor growth (7‑9, 11, 14, 15).
Human FGF‑BP Antibody
R&D Systems | Catalog # MAB1593
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Western Blot
Cited:
Immunohistochemistry, Western Blot, ELISA Capture
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 196519
Loading...
Product Specifications
Immunogen
E. coli-derived recombinant human FGF-BP
Val35-Cys234
Accession # Q14512
Val35-Cys234
Accession # Q14512
Specificity
Detects human FGF-BP in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant rat FGF-BP is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for Human FGF‑BP Antibody
Detection of Human FGF-BP by Western Blot
miR-217 targets KLF5 by binding to its 3’UTR.A. miR-217 decreased the KLF5, FGF-BP and Cyclin D1 protein levels in HCC1806 and HCC1937 TNBC cells. KLF5, FGF-BP and Cyclin D1 protein levels were detected by using WB. beta -actin was used as the loading control. B. The putative wild type binding sites of miR-217 on KLF5 3’UTR and its mutants. C. miR-217 mimics significantly inhibits the KLF5 3’UTR luciferase reporter activity through the second putative binding site. HEK293T cells were transfected with miR-217 mimics and pMIR-KLF5 3’-UTR or miR-217 binding sites mutated pMIR-KLF5 3’-UTR reporters (mut1, mut2 or mut1,2) together with the pCMV-Renilla control. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0176395), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse FGF-BP by Immunohistochemistry
mTORC1-STAT3-FGFBP1 pathway regulates angiogenesis in an OVA-induced chronic asthma model.A The timeline to establish OVA-induced chronic asthma models and therapeutic interventions (see the “Materials and methods” section for details). The mice were divided into three groups: the control group (Control), OVA-induced chronic asthma group (OVA), and rapamycin-treated group (Rapa). B The total number of leukocytes and eosinophil count in the BALF were counted using Wright–Giemsa staining. C Representative photographs of H&E staining (upper panels) and Masson’s staining (lower panels) of lung tissues (scale bar: 100 μm). D Inflammation score (left panels) and Wat/Pbm (right panels) of lung tissues. E Immunoblotting of the indicated proteins in lung tissues. F IHC analysis of the indicated proteins in lung tissues (scale bar: 100 μm). n = 8 mice per group. Results are shown as mean ± SD. **P < 0.01; ***P < 0.001; ****P < 0.0001. G Schematic illustration of activated mTORC1-STAT3-FGFBP1 signaling pathway promotes angiogenesis in airway epithelial cells. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34341336), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse FGF-BP by Immunohistochemistry
PLA promotes angiogenesis through FGFBP1.A NCI-H292 cells, stably expressed shRNA targeting FGFBP1 (shFGFBP1) or a control shRNA (shSc), were treated with 20 μg/mL PLA for 24 h. Western blot (upper panel) and ELISA (lower panel) were performed to detect the protein levels of FGFBP1 in cell lysates and supernatants, respectively. B–E NCI-H292/shFGFBP1 and NCI-H292/shSc cells were treated with PLA (20 μg/mL) for 24 h and the cell-conditioned media were collected for tube formation assay (B, C) and CAM assay (D, E). B, D Representative micrographs of tube formation assay (B) and CAM assay (D). C, E Quantitations of total branching points of tube formation assay (C) and new vessels of CAM assay (E). F NCI-H292 cells infected with lentivirus harboring a vector encoding FGFBP1 (LvFGFBP1) or the empty vector (LvNC). Western blot (upper panel) and ELISA (lower panel) were performed to detect the protein levels of FGFBP1 in cell lysates and supernatants, respectively. (G–J) The cell-conditioned media of NCI-H292/LvFGFBP1 and NCI-H292/LvNC cells were collected for tube formation assay (G, H) and CAM assay (I, J). G, I Representative micrographs of tube formation assay (G) and CAM assay (I). H, J Quantitation of total branching points of tube formation assay (H) and new vessels of CAM assay (J). n = 6 chick embryos per group. Results are shown as mean ± SD. ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34341336), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse FGF-BP by Immunohistochemistry
PLA promotes angiogenesis through FGFBP1.A NCI-H292 cells, stably expressed shRNA targeting FGFBP1 (shFGFBP1) or a control shRNA (shSc), were treated with 20 μg/mL PLA for 24 h. Western blot (upper panel) and ELISA (lower panel) were performed to detect the protein levels of FGFBP1 in cell lysates and supernatants, respectively. B–E NCI-H292/shFGFBP1 and NCI-H292/shSc cells were treated with PLA (20 μg/mL) for 24 h and the cell-conditioned media were collected for tube formation assay (B, C) and CAM assay (D, E). B, D Representative micrographs of tube formation assay (B) and CAM assay (D). C, E Quantitations of total branching points of tube formation assay (C) and new vessels of CAM assay (E). F NCI-H292 cells infected with lentivirus harboring a vector encoding FGFBP1 (LvFGFBP1) or the empty vector (LvNC). Western blot (upper panel) and ELISA (lower panel) were performed to detect the protein levels of FGFBP1 in cell lysates and supernatants, respectively. (G–J) The cell-conditioned media of NCI-H292/LvFGFBP1 and NCI-H292/LvNC cells were collected for tube formation assay (G, H) and CAM assay (I, J). G, I Representative micrographs of tube formation assay (G) and CAM assay (I). H, J Quantitation of total branching points of tube formation assay (H) and new vessels of CAM assay (J). n = 6 chick embryos per group. Results are shown as mean ± SD. ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34341336), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of FGF-BP by Western Blot
HDACi in combination with BRD4i inhibit the KLF5 expression and function and the survival of BLBC cells. A, HDACi were combined with compound 870 to regulate the expression of KLF5 and its downstream target genes (FGF-BP1, Cyclin D1, and p21). HCC1937 and HCC1806 cells were treated with HDACi and compound 870 for 24 h at the indicated concentrations. The protein expression was measured by Western blotting, and cell viability was assessed after 24 h by the SRB assay. B, KLF5 knockdown decreased the cytotoxicity of HDACi in BLBC cell lines. KLF5 was knocked down by two different siRNAs in HCC1937 and HCC1806 cells and cell lysates were collected for Western blotting. The cells were treated with HDACi for 48 h to measure cell viability by the SRB assay. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35342356), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of FGF-BP by Western Blot
Both HDACi and HDAC1 knockdown downregulated the expression of KLF5 protein and its downstream targets genes. A, HDACi inhibited KLF5-mediated downstream target gene (FGF-BP1, Cyclin D1, and p21 expression changes. HCC1937 and HCC1806 cells were treated with HDACi for 48 h at the indicated concentrations. The protein expression was measured by Western blotting. B, HDAC1 knockdown by three different siRNAs in HCC1937 and HCC1806 cells for 48 h; cell lysates were collected for western blotting, which indicated that KLF5 and its downstream target gene (FGF-BP1 and Cyclin D1) expression were blocked. C, HDAC1 knockdown-induced reduction in KLF5 expression in BLBC was inhibited by proteasome inhibitor. HDAC1 was knocked down by three different siRNAs in HCC1937 and HCC1806 cells for 24 h. Subsequently, MG132 (3 µM) was used to treat the cells for 24 h. Cell lysates were collected for Western blotting. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35342356), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of FGF-BP by Western Blot
Both HDACi and HDAC1 knockdown downregulated the expression of KLF5 protein and its downstream targets genes. A, HDACi inhibited KLF5-mediated downstream target gene (FGF-BP1, Cyclin D1, and p21 expression changes. HCC1937 and HCC1806 cells were treated with HDACi for 48 h at the indicated concentrations. The protein expression was measured by Western blotting. B, HDAC1 knockdown by three different siRNAs in HCC1937 and HCC1806 cells for 48 h; cell lysates were collected for western blotting, which indicated that KLF5 and its downstream target gene (FGF-BP1 and Cyclin D1) expression were blocked. C, HDAC1 knockdown-induced reduction in KLF5 expression in BLBC was inhibited by proteasome inhibitor. HDAC1 was knocked down by three different siRNAs in HCC1937 and HCC1806 cells for 24 h. Subsequently, MG132 (3 µM) was used to treat the cells for 24 h. Cell lysates were collected for Western blotting. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35342356), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human FGF‑BP Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: Recombinant Human FGF-BP (Catalog # 1593-FB)
Sample: Recombinant Human FGF-BP (Catalog # 1593-FB)
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Loading...
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: FGF-BP
References
- Abuharbeid, S. et al. (2006) Int. J. Biochem. Cell Biol. 38:1463.
- Wu, D. et al. (1991) J. Biol. Chem. 266:16778.
- Tassi, E. et al. (2006) Cancer Res. 66:1191.
- Lametsch, R. et al. (2000) J. Biol. Chem. 275:19469.
- Xie, B. et al. (2006) J. Biol. Chem. 281:1137.
- Aigner, A. et al. (2002) Histochem. Cell Biol. 117:1.
- Beer, H-D. et al. (2005) Oncogene 24:5269.
- Ray, P.E. et al. (2006) Am. J. Physiol. Regul. Integr. Comp. Physiol. 290:R105.
- Tassi, E. et al. (2007) Am. J. Physiol. Regul. Integr. Comp. Physiol. 293:R775.
- Kurtz, A. et al. (2004) Neoplasia 6:595.
- Tassi, E. et al. (2001) J. Biol. Chem. 276:40247.
- Mongiat, M. et al. (2001) J. Biol. Chem. 276:10263.
- Kurtz, A. et al. (1997) Oncogene 14:2671.
- Aigner, A. et al. (2001) Int. J. Cancer 92:510.
- Czubayko, F. et al. (1997) Nat. Med. 3:1137.
Long Name
Fibroblast Growth Factor Binding Protein
Alternate Names
FGF-BP1, FGFBP, FGFBP-1, FGFBP1, HBp17
Gene Symbol
FGFBP1
UniProt
Additional FGF-BP Products
Product Documents for Human FGF‑BP Antibody
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Human FGF‑BP Antibody
For research use only
Related Research Areas
Citations for Human FGF‑BP Antibody
Customer Reviews for Human FGF‑BP Antibody
There are currently no reviews for this product. Be the first to review Human FGF‑BP Antibody and earn rewards!
Have you used Human FGF‑BP Antibody?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Cellular Response to Hypoxia Protocols
- R&D Systems Quality Control Western Blot Protocol
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars
Loading...